In drug development, we create human test systems that already allow statements to be made in preclinical research about the effect and side effects of potential highly specific drug candidates that cannot be provided in animal models. We achieve this by developing organoid in vitro models, from three-dimensional in vitro models of human tissue to organ-on-a-chip systems. Our many years of experience in molecular cell technology enable us to precisely develop receptor-based assays for drug validation as well as production cell lines for biologicals.
New innovative therapeutic approaches are developed at the IGB using viruses. Our long-standing experience in virus engineering enables the tailor-made design of viruses for targeted prevention (vaccines) and therapy (oncolytic viruses).
For the targeted transport and controlled release of active substances (drug delivery and release), we formulate active substances, for example, in a matrix consisting of biobased, polymeric or silicate materials.